Gastroenterology Education and CPD for trainees and specialists » Regorafenib Gives Colorectal Cancer Patients More Time

- Gastroenterology Education and CPD for trainees and specialists - https://www.gastrotraining.com -

Regorafenib Gives Colorectal Cancer Patients More Time

(MedPage Today) — The investigational drug regorafenib extended overall survival in patients with treatment-refractory advanced colorectal cancer by 1.4 months in a phase III trial, according to its manufacturer.

Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com